Skip to content
Disclosery

Alerce Investment Management, L.P.

Follow

13F filer, CIK 1844002, Chicago, IL

Alerce Investment Management, L.P. reported $51,015,887 across 5 holdings for the quarter ended 2024-06-30, in a 13F-HR filed 2024-08-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000895345-24-000350

Period
2024-06-30
Reported value
$51M
Holdings
5
Top 10 weight
100%
New
1
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
VERONA PHARMA PLCnew+213,000$3.08M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
AKBAreduced-7,457,213-$7.61M
RNTXexited-830,466-$5.51M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2024

Share positions as resolved from 13F-HR 0000895345-24-000350, largest first. % of portfolio is the value over $51,015,887, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 7,056,024 shares; 2023Q2: 7,056,024 shares; 2023Q3: 7,056,024 shares; 2023Q4: 7,406,024 shares; 2024Q1: 7,406,024 shares; 2024Q2: 7,406,024 shares 7,406,024$36.3M71.13%0Timeline
AKBAAKEBIA THREAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 16,205,119 shares; 2023Q2: 16,205,119 shares; 2023Q3: 16,205,119 shares; 2023Q4: 16,205,119 shares; 2024Q1: 13,205,119 shares; 2024Q2: 5,747,906 shares 5,747,906$5.86M11.49%-7,457,213Timeline
AMERICAN WELL CORPAMERICAN WELL CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 10,475,717 shares; 2023Q2: 10,475,717 shares; 2023Q3: 10,475,717 shares; 2023Q4: 10,475,717 shares; 2024Q1: 10,475,717 shares; 2024Q2: 10,475,717 shares 10,475,717$3.4M6.67%0
VERONA PHARMA PLCVERONA PHARMA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 213,000 shares 213,000$3.08M6.04%new
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 1,630,830 shares; 2023Q2: 1,630,830 shares; 2023Q3: 1,630,830 shares; 2023Q4: 1,630,830 shares; 2024Q1: 1,630,830 shares; 2024Q2: 1,630,830 shares 1,630,830$2.38M4.67%0Timeline

Sold out in Q2 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RNTXREIN THERAPEUTICS INC830,466$5.51Mshares

How Q2 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000895345-24-000350 base2024-08-14acceptance time not in the bulk data set